How to Initiate Cannabidiol for Treatment-Resistant Youth Anxiety
How should clinicians select and dose adjunctive cannabidiol for young people with treatment-resistant anxiety disorders?
Some young people with anxiety disorders remain significantly symptomatic despite cognitive-behavioral therapy and antidepressant treatment. This guide applies to patients aged 12 to 25 years with DSM-5 anxiety disorders who have not improved in the current episode of care despite standard treatment and summarizes the cannabidiol workflow used in this trial.
-
Confirm treatment-resistant anxiety and basic eligibility
Use a structured assessment to confirm a DSM-5 anxiety disorder, as was done with the SCID-5 in the trial. Reserve this approach for patients aged 12 to 25 years who have shown no improvement during the current episode despite CBT and/or antidepressant medication, operationalized in the study as a CGI-I score of 3 or higher.
-
Exclude patients with trial-defined safety contraindications
Do not proceed if the patient has a schizophrenia spectrum disorder, delusional disorder, bipolar I disorder, substance/medication-induced psychotic disorder, prior sensitivity to CBD or cannabis-derived products, acute suicidality, severe drug or alcohol dependence, pregnancy or lactation, inadequate contraception if sexually active, unstable systemic medical illness, medically significant abnormal liver or thyroid findings, or severe disturbance preventing protocol adherence. The study also excluded patients taking antipsychotics, anxiolytics, mood stabilizers, or other medications that could not be safely coadministered because of CBD-related metabolic interactions.
-
Stabilize concurrent usual care before starting
Continue treatment as usual rather than replacing it, mirroring the adjunctive design of the trial. If the patient is taking an antidepressant, keep the dose stable for at least 6 weeks before enrollment, as required in the study, while ongoing CBT and psychosocial care continue.
-
Start oral cannabidiol at 200 mg daily
Begin with 200 mg/day of oral cannabidiol for all patients. In the trial, all participants received high-purity oral CBD capsules and treatment was planned for 12 weeks, followed by gradual weaning over 1 week.
-
Escalate the dose in 200 mg increments based on improvement
Increase the dose only if the patient has not shown clinically meaningful improvement, defined in the study as a CGI-I score of 3 or higher. The maximum dose was 400 mg/day at week 1, 600 mg/day at week 4, and 800 mg/day at week 8.
-
Reassess response through week 12
Review the patient at weeks 4, 8, and 12, as in the trial, and track anxiety severity with a transdiagnostic measure such as the OASIS alongside clinician-rated improvement. In this study, most participants required escalation, with 19 titrated to 800 mg/day and 10 remaining at 600 mg/day or 400 mg/day by week 12 based on treatment response and/or adverse events.
-
Plan discontinuation rather than indefinite continuation
At the end of the 12-week treatment period, taper cannabidiol over 1 week, consistent with the study protocol. The trial did not include ongoing CBD use after week 12, and participants were not using CBD between treatment end and the week-26 follow-up.
Clinical Considerations
- The trial was open-label and uncontrolled, so this workflow cannot establish that cannabidiol caused the observed improvement.
- This guide applies to adjunctive use in young people aged 12 to 25 years with treatment-resistant anxiety disorders and should not be generalized beyond that population.
- Improvements in anxiety, depressive symptoms, and functioning were not sustained at 6 months in the subset assessed after treatment ended.
- The study did not identify a plasma CBD concentration or higher dose that predicted greater anxiety improvement.
Bottom Line
In treatment-resistant anxiety disorders among young people, the studied cannabidiol approach was adjunctive treatment for 12 weeks starting at 200 mg/day and titrating by 200-mg steps up to 800 mg/day when CGI-I still showed inadequate improvement.
